## J Mark Elwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/349628/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic models for breast cancer: a systematic review. BMC Cancer, 2019, 19, 230.	2.6	107
2	Factors related to the presentation of thin and thick nodular melanoma from a populationâ€based cancer registry in Queensland Australia. Cancer, 2009, 115, 1318-1327.	4.1	83
3	Commentary: On representativeness. International Journal of Epidemiology, 2013, 42, 1014-1015.	1.9	62
4	Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer, 2016, 16, 129.	2.6	40
5	Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?. BMC Cancer, 2018, 18, 58.	2.6	33
6	Comparison of oropharyngeal and oral cavity squamous cell cancer incidence and trends in New Zealand and Queensland, Australia. Cancer Epidemiology, 2014, 38, 16-21.	1.9	28
7	Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 817-824.	2.5	25
8	The burden of nonâ€melanoma skin cancers in Auckland, New Zealand. Australasian Journal of Dermatology, 2018, 59, 210-213.	0.7	25
9	Rapid increase in endometrial cancer incidence and ethnic differences in New Zealand. Cancer Causes and Control, 2019, 30, 121-127.	1.8	24
10	Treatment and survival disparities by ethnicity in New Zealand women with stage l–III breast cancer tumour subtypes. Cancer Causes and Control, 2017, 28, 1417-1427.	1.8	19
11	Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute?. PLoS ONE, 2016, 11, e0153206.	2.5	17
12	Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to â€`autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA). Vaccine, 2018, 36, 5796-5802.	3.8	16
13	Bias in survival estimates created by a requirement for consent to enter a clinical breast cancer registry. Cancer Epidemiology, 2019, 58, 178-183.	1.9	16
14	Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index. BMC Cancer, 2018, 18, 897.	2.6	15
15	Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. Targeted Oncology, 2020, 15, 279-299.	3.6	14
16	The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer. New Zealand Medical Journal, 2018, 131, 51-60.	0.5	14
17	Alcohol consumption and risk of melanoma among women: pooled analysis of eight case–control studies. Archives of Dermatological Research, 2015, 307, 819-828.	1.9	13
18	Characteristics of and differences between Pasifika women and New Zealand European women diagnosed with breast cancer in New Zealand. New Zealand Medical Journal, 2017, 130, 50-61.	0.5	13

J Mark Elwood

#	Article	IF	CITATIONS
19	Investigations and referral for suspected cancer in primary care in New Zealand-A survey linked to the International Cancer Benchmarking Partnership. European Journal of Cancer Care, 2017, 26, e12634.	1.5	12
20	Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand. Breast Cancer, 2021, 28, 387-397.	2.9	12
21	The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A protocol for a systematic review of human observational studies. Environment International, 2021, 157, 106828.	10.0	12
22	<i>In situ</i> and invasive melanoma in a highâ€risk, New Zealand, population: A populationâ€based study. Australasian Journal of Dermatology, 2019, 60, 38-44.	0.7	11
23	Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10. PLoS ONE, 2016, 11, e0150734.	2.5	10
24	Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study. BMC Cancer, 2018, 18, 76.	2.6	10
25	Screening for anaplastic lymphoma kinase ( <i>ALK</i> ) gene rearrangements in nonâ€smallâ€cell lung cancer in New Zealand. Internal Medicine Journal, 2020, 50, 716-725.	0.8	9
26	The Scientific Basis for Occupational Exposure Limits for Hydrogen Sulphide—A Critical Commentary. International Journal of Environmental Research and Public Health, 2021, 18, 2866.	2.6	9
27	Nitrates in drinking water and cancers of the colon and rectum: a meta-analysis of epidemiological studies. Cancer Epidemiology, 2022, 78, 102148.	1.9	9
28	Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer Epidemiology, 2018, 57, 24-32.	1.9	8
29	Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand. BMC Cancer, 2020, 20, 658.	2.6	8
30	Urban Rural Differences in Breast Cancer in New Zealand. International Journal of Environmental Research and Public Health, 2016, 13, 1000.	2.6	7
31	The characteristics, management and outcomes of older women with breast cancer in New Zealand. Maturitas, 2018, 112, 64-70.	2.4	7
32	Associated Factors and Survival Outcomes for Breast Conserving Surgery versus Mastectomy among New Zealand Women with Early-Stage Breast Cancer. International Journal of Environmental Research and Public Health, 2021, 18, 2738.	2.6	7
33	Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. British Journal of Cancer, 2022, 126, 1774-1782.	6.4	7
34	Increasing incidence of endometrial carcinoma in a highâ€risk New Zealand community. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 250-257.	1.0	6
35	Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in MÄori and Pacifica in New Zealand. PLoS ONE, 2021, 16, e0251357.	2.5	6
36	Comparison of cancer survival in New Zealand and Australia, 2006-2010. New Zealand Medical Journal, 2014, 127, 14-26.	0.5	6

J Mark Elwood

#	Article	IF	CITATIONS
37	Microwaves in the cold war: the Moscow embassy study and its interpretation. Review of a retrospective cohort study. Environmental Health, 2012, 11, 85.	4.0	5
38	Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Research and Treatment, 2022, 193, 225-235.	2.5	5
39	Bioelectromagnetics Research within an Australian Context: The Australian Centre for Electromagnetic Bioeffects Research (ACEBR). International Journal of Environmental Research and Public Health, 2016, 13, 967.	2.6	4
40	Health effects of radiofrequency electromagnetic energy. New Zealand Medical Journal, 2019, 132, 64-72.	0.5	4
41	Mobile phones, brain tumors, and the limits of science. Bioelectromagnetics, 2014, 35, 379-383.	1.6	3
42	Cancer mortality and incidence trends comparing New Zealand and Australia for the period 2000-2007. New Zealand Medical Journal, 2014, 127, 9-19.	0.5	3
43	Receipt of radiotherapy after mastectomy in women with breast cancer: Populationâ€based cohort study in New Zealand. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e99-e107.	1.1	2
44	Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. Cancer Epidemiology, 2020, 69, 101847.	1.9	2
45	Mobile phone use and trends in the incidence of cancers of the parotid and other salivary glands. Cancer Epidemiology, 2021, 73, 101961.	1.9	2
46	The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand). Skin Health and Disease, 2023, 3, .	1.5	2
47	Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival. International Journal of Environmental Research and Public Health, 2020, 17, 7962.	2.6	1
48	Missing data on body mass index in a breast cancer register: how is it associated with patient characteristics and clinical outcomes?. New Zealand Medical Journal, 2017, 130, 21-29.	0.5	1
49	Animal studies of exposures to radiofrequency fields. New Zealand Medical Journal, 2019, 132, 98-100.	0.5	1
50	Screening for lung cancer: Comment on results of de-Torres etÂal., 2013. Respiratory Medicine, 2017, 126, 139.	2.9	0
51	Comment on: Maternal Exposure to Domestic Hair Cosmetics and Occupational Endocrine Disruptors Is Associated with a Higher Risk of Hypospadias in the Offspring. Int. J. Environ. Res. Public Health 2017, 14, 27. International Journal of Environmental Research and Public Health, 2017, 14, 1061.	2.6	0
52	High incidence of medulloblastoma in MÄori and Pacific populations in New Zealand. New Zealand Medical Journal, 2017, 130, 105-106.	0.5	0
53	Is there a syndrome caused by radiofrequency electromagnetic fields?. New Zealand Medical Journal, 2020, 133, 95-102.	0.5	0